Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00648700 | Fasting Study of Levothyroxine Sodium Tablets 300 μg to Levothroid® Tablets 300 μg | PHASE1 | COMPLETED | 32 | — | — | Aug 1, 2005 | Sep 1, 2005 | Apr 24, 2024 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Levothyroxine Sodium Tablets 300 μg |
| 2 | ACTIVE_COMPARATOR | Levothroid® Tablets 300 μg |
| Name | Type | Description |
|---|---|---|
| Levothyroxine Sodium Tablets 300 μg | DRUG | 2x300mcg, single dose fasting |
| Levothroid® Tablets 300 μg | DRUG | 2x300mcg, single dose fasting |
Inclusion Criteria: 1. Age: 18-50 years. 2. Sex: Men and/or non-pregnant, non-lactating women. 1. Women of childbearing potential must have negative serum β human chorionic gonadotropin (HCG) pregnancy tests performed within 14 days prior to of the study and on the evening prior to each dose ad...